INVERSAGO-PHARMA-INC.
29.9.2020 14:02:30 CEST | Business Wire | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH).
The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Recruitment is ongoing and will enroll healthy participants in Canada, from 18 to 55 years old. Subjects will initially be randomized to receive a single dose of placebo or one of 5 dose levels of INV-101.
“With the launch of this first-in-human trial, Inversago is now a clinical-stage company, and confirms its lead in the comeback of small molecule peripheral CB1 blockers”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma.
“Dosing of our first patient with INV-101 represents an important milestone to accomplish the Company’s vision: offering a potentially meaningful therapeutic option to underserved patient populations, like in PWS and NASH" said Carlo Incerti, M.D., Chairman of the Board of Inversago. "This study is the first step in the clinical development of our peripherally-acting CB1 blockers, and we expect it to provide important information about its safety and pharmacokinetics profile", concluded Dr. Incerti.
The Company’s second program, INV-202, is presently in IND-enabling preclinical studies, while other programs are in earlier stages of development. With its current pipeline, Inversago is well positioned to fully exploit peripheral CB1 blockade for a wide range of underserved metabolic indications with differentiated products.
About INV-101
INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and NASH. It is specifically designed to interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com .
Picture of our CEO and company logotype available for download at: inversago.com/en/media/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005408/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Icon Solutions Showcases How Banks Can Accelerate Digital Asset Innovation with IPF9.6.2026 11:30:00 CEST | Press release
Banks can now deploy digital asset payments faster, without risking fragmentation Icon Solutions – the UK fintech enabling banks to design and implement state-of-the-art payment systems – has released a reference implementation showing how banks can use the Icon Payments Framework (IPF) to accelerate support for payments processing using distributed ledger technology (DLT)-based digital assets. As IPF is agnostic to both the type of digital asset and the DLT network on which they are issued, the risk of fragmentation is reduced as adoption scales. There is growing momentum for digital assets such as stablecoins, tokenised deposits, deposit tokens and central bank digital currencies (CBDCs) to enable faster, cheaper and smarter payments. Yet the emergence of different digital asset types and DLT networks – which must also work with existing financial infrastructure – creates fragmentation and operational complexity for banks. This is compounded by legacy vendor solutions that limit choi
monday.com Appoints Ben Barnett General Manager of EMEA to Drive Next Phase of Regional Growth9.6.2026 10:00:00 CEST | Press release
In 2025, monday.com saw 26% YoY revenue growth in EMEABarnett will be a driving force in monday.com’s biggest transformation yet monday.com (Nasdaq: MNDY), the AI work platform that turns strategy into execution at scale, today announced Ben Barnett’s appointment to General Manager (GM) of Europe, the Middle East and Africa, marking a major milestone in the company’s global expansion. Ben, who has been with monday.com for five years, brings a decade of experience in senior B2B sales roles at software companies and has overseen significant, sustained growth at monday.com in the UK and Ireland since joining in 2021. In his new position, Ben’s priorities include delivering the monday.com’s EMEA go-to-market strategy, fostering key partnerships, and bolstering its newly announced AI work platform. He is based in London. Ben’s promotion comes as monday.com builds on a period of rapid regional success, with EMEA revenue up 26% year-on-year in 2025. Last year, monday.com expanded its regional
Interactive Brokers Launches Commission-Free iShares ETFs from BlackRock through Recurring Investment Feature Across Europe9.6.2026 10:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of Commission-Free ETFs within its Recurring Investment feature for eligible individual investors across the European Economic Area. Investors can now access more than 500 commission-free iShares ETFs from BlackRock spanning a broad range of asset classes and strategies, including bonds, equities, themes and sectors. The iShares ETFs available on the IBKR platform give individual investors an accessible, cost-efficient way to build well-diversified portfolios. Since investors pay no trading commissions, more of their capital stays invested and compounding over time, while a broad selection of funds across asset classes makes it straightforward to construct and rebalance portfolios. iShares ETFs are available commission-free through IBKR's Recurring Investments feature, allowing investors to automate their periodic ETF contributions. Clients can select individual ETFs or ETF portfolios, set a cont
Forrester Reveals The Top 10 Highest-Performing Brands In Its 2026 Global Total Experience Score Rankings At Its CX Events9.6.2026 09:30:00 CEST | Press release
Introduced last year, the Total Experience Score evaluates the combined influence of brand and customer experience on overall brand perception among both noncustomers and customers According to Forrester’s (Nasdaq: FORR) 2026 global Total Experience Score rankings of 375 brands evaluated across Asia Pacific, Europe, and North America in 2025 and 2026, 41% improved their scores while only 3% declined. A compelling total experience — calculated by combining Forrester’s Customer Experience Index (CX Index™), Brand Experience Index (BX Index™), and, for the first time, the new Employee Experience Index (EX Index™) into a unified view of performance — can drive outsized growth for brands. While brand experience and customer experience can each drive revenue independently, the impact multiplies when they are orchestrated together as a unified total experience. In the US, for example, companies delivering a strong total experience see significantly higher returns from retention and enrichment
IQM Announces Novel Quantum Error Correction Approach Toward Fault-Tolerant Quantum Computing9.6.2026 09:00:00 CEST | Press release
New approach delivers cutting edge performance, while significantly reducing hardware complexity IQM Quantum Computers, the global leader in superconducting quantum computers, has developed a novel quantum error-correcting code that achieves up to three orders of magnitude lower logical error rates than the surface code, also requiring up to eight times fewer physical qubits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609533201/en/ IQM´s breakthrough technology, called barbell codes. Unlike many alternative high-performance quantum error-correction approaches, the new code also maintains a comparatively low hardware complexity, marking a significant advancement toward scalable fault-tolerant quantum computing. Quantum error correction remains one of the defining challenges in the race toward practical quantum computing. Errors introduced by noise must be corrected faster than they accumulate, a requirement that previo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom